58576-49-1

Upstream product

• 81085-35-0 (E)-4-methylsulfanylbut-2-enoic acid 
• 3198-47-8 α-amino-γ-methylmercapto-butyronitrile 
• 454-29-5 2-amino-4-mercaptobutyric acid 
• 4727-41-7 dimethylsulfonioacetate 
• 408350-94-7 2-(2-methylsulfanyl-ethyl)-acetoacetic acid ethyl ester 
• 859200-50-3 (2-methylsulfanyl-ethyl)-malonic acid 
• 130629-26-4 ethyl 2-cyano-4-(methylthio)butyrate 
• 722497-10-1 2-acetylamino-2-cyano-4-methylsulfanyl-butyric acid ethyl ester 
• 82102-39-4 acetylamino-(2-methylsulfanyl-ethyl)-malonic acid diethyl ester 
• 1017-76-1 S-benzyl homocysteine 
• 4703-38-2 N-benzoylmethionine 
• 74-93-1 methylthiol 
• 5809-59-6 3-cyano-3-hydroxy-1-propene 
• 70982-53-5 (S)-2-amino-3-butenoic acid 

Downstream Products

• 100568-90-9 N-[(2,4,5-trichloro-phenoxy)-acetyl]-DL-methionine 
• 4703-31-5 N-(N-benzoyl-glycyl)-methionine 
• 65055-24-5 N-salicyloyl-dl-methionine 
• 5540-05-6 N-(N-benzyloxycarbonyl-glycyl)-methionine 
• 56830-84-3 5-(2-(methylthio)ethyl)-2-thioxoimidazolidin-4-one 
• 83795-52-2 N-(4-nitro-benzoyl)-methionine 
• 65055-00-7 N-trans-cinnamoyl-DL-methionine 
• 59900-30-0 N-(1-(methylthio)-4-oxopentan-3-yl)acetamide 
• 31414-30-9 N-[(4-chloro-phenoxy)-acetyl]-DL-methionine 
• 62625-13-2 NSC87887 
• 63649-07-0 methionine benzyl ester 
• 3309-53-3 N-cyclohexyloxycarbonyl-methionine 
• 6297-55-8 N-phenylmethanesulfonyl-DL-methionine 
• 10070-06-1 N-thiobenzoyl-methionine 

Relevant academic research and scientific papers

Highly Stable Zr(IV)-Based Metal-Organic Frameworks for Chiral Separation in Reversed-Phase Liquid Chromatography

Separation of racemic mixtures is of great importance and interest in chemistry and pharmacology. Porous materials including metal-organic frameworks (MOFs) have been widely explored as chiral stationary phases (CSPs) in chiral resolution. However, it remains a challenge to develop new CSPs for reversed-phase high-performance liquid chromatography (RP-HPLC), which is the most popular chromatographic mode and accounts for over 90% of all separations. Here we demonstrated for the first time that highly stable Zr-based MOFs can be efficient CSPs for RP-HPLC. By elaborately designing and synthesizing three tetracarboxylate ligands of enantiopure 1,1′-biphenyl-20-crown-6, we prepared three chiral porous Zr(IV)-MOFs with the framework formula [Zr6O4(OH)8(H2O)4(L)2]. They share the same flu topological structure but channels of different sizes and display excellent tolerance to water, acid, and base. Chiral crown ether moieties are periodically aligned within the framework channels, allowing for stereoselective recognition of guest molecules via supramolecular interactions. Under acidic aqueous eluent conditions, the Zr-MOF-packed HPLC columns provide high resolution, selectivity, and durability for the separation of a variety of model racemates, including unprotected and protected amino acids and N-containing drugs, which are comparable to or even superior to several commercial chiral columns for HPLC separation. DFT calculations suggest that the Zr-MOF provides a confined microenvironment for chiral crown ethers that dictates the separation selectivity.

Direct monitoring of biocatalytic deacetylation of amino acid substrates by1H NMR reveals fine details of substrate specificity

Amino acids are key synthetic building blocks that can be prepared in an enantiopure form by biocatalytic methods. We show that thel-selective ornithine deacetylase ArgE catalyses hydrolysis of a wide-range ofN-acyl-amino acid substrates. This activity was revealed by1H NMR spectroscopy that monitored the appearance of the well resolved signal of the acetate product. Furthermore, the assay was used to probe the subtle structural selectivity of the biocatalyst using a substrate that could adopt different rotameric conformations.

METHOD FOR PRODUCING METHIONINE

An object of the present invention to provide a method for producing methionine with consideration given to the environment. The production method of the present invention comprises a removal step of blowing an inert gas into a liquid containing 5-(2-methylmercaptoethyl)hydantoin and thereby diffusing ammonia remaining in the liquid to obtain an emission gas containing the ammonia, and a recovery step of bringing the emission gas into contact with a washing liquid to recover ammonia contained in the emission gas.

METHOD FOR MANUFACTURING METHIONINE

An object of the present invention is to provide a method for manufacturing methionine capable of achieving an improvement in ammonia removal efficiency. The manufacturing method of the present invention comprises a removal step of supplying a liquid containing a methionine salt, which is obtained by reacting 3-methylmercaptopropionaldehyde and hydrocyanic acid, or a compound obtained by reacting 3-methylmercaptopropionaldehyde and hydrocyanic acid, with carbon dioxide and ammonia to obtain a liquid containing 5-(2-methylmercaptoethyl)hydantoin and then hydrolyzing the 5-(2-methylmercaptoethyl)hydantoin, to a diffusion tower from an upper portion thereof while supplying a stripping gas to the diffusion tower from a lower portion thereof to remove ammonia contained in the liquid through stripping, and the stripping gas contains a process gas generated in a process of manufacturing methionine.

Process for producing L-methionine from methional

A method is useful for the biocatalytic synthesis of proteinogenic L-amino acids, such as L-alanine, L-valine, L-methionine, L-leucine, L-isoleucine or L-phenylalanine from a respective aldehyde and carbon dioxide. In particular, the method is useful for the biocatalytic synthesis of L-methionine from 3-methylthio-propanal (“methional”) and carbon dioxide.

STORAGE-STABLE FORM OF 3-METHYLTHIOPROPIONALDEHYDE

A chemical compound of formula (I), and specific compositions including 3-methylthiopropionaldehyde, 3-methylthiopropane-1,1-diol, a compound of formula I and water, and processes for producing same and also the use of same may be used for the production of 2-hydroxy-4-(methylthio)butyronitrile, methionine hydantoin, methionine. Protected forms may be used for the storage and/or transport of 3-methylthiopropionaldehyde.

Motobamide, an Antitrypanosomal Cyclic Peptide from a Leptolyngbya sp. Marine Cyanobacterium

Motobamide (1), a new cyclic peptide containing a C-prenylated cyclotryptophan residue, was isolated from a marine Leptolyngbya sp. cyanobacterium. Its planar structure was established by spectroscopic and MS/MS analyses. The absolute configuration was elucidated based on a combination of chemical degradations, chiral-phase HPLC analyses, spectroscopic analyses, and computational chemistry. Motobamide (1) moderately inhibited the growth of bloodstream forms of Trypanosoma brucei rhodesiense (IC50 2.3 μM). However, it exhibited a weaker cytotoxicity against normal human cells (IC50 55 μM).

Safe and Effective Method of Treating Ulcerative Colitis with Anti-IL12/IL23 Antibody

Described are methods and compositions for clinical proven safe and effective treatment of ulcerative colitis, particularly moderately to severely active ulcerative colitis in patients who have had an inadequate response to or are intolerant of a conventional or existing therapy by intravenous and/or subcutaneous administration of an anti-IL-12/IL-23p40 antibody.

PROCESS FOR THE PREPARATION OF METHIONINE

The present invention relates to a process for the preparation of methionine comprising the step of contacting a solution or suspension comprising 2-amino-4-(methylthio)butanenitrile and/or 2-amino- 4-(methylthio)butaneamide with water in the presence of a catalyst to give a methionine comprising mixture, wherein the catalyst comprises CeO2 comprising particles, wherein the CeO2 comprising particles have a BET surface area of from 175 to 300 +/- 10% m2/g measured according to DIN ISO 9277-5 (2003), a mean maximum Feret diameter xFmax, mean of from 3 +/- 10% to 40 +/- 10% nm and a mean minimum Feret diameter xFmin, mean of from 2 +/- 10% to 30 +/- 10% nm, both measured according to DIN ISO 9276-6 (2012).

SALT-FREE PRODUCTION OF METHIONINE FROM METHIONINE NITRILE

The invention refers to the use of a particulate catalyst containing 60.0 to 99.5 wt.% ZrO2 stabilised with an oxide of the element Hf and at least one oxide of the element M, wherein M = Ce, Si, Ti, or Y, for the hydrolysis reaction of methionine amide to methionine, wherein the median particle size x50 of the particulate catalyst is in the range of from 0.8 to 9.0 mm, preferably of from 1.0 to 7.0 mm. The invention also refers to a process for preparing methionine comprising a step of contacting a solution or suspension comprising methionine amide and water with said particulate catalyst to provide a reaction mixture comprising methionine and/or its ammonium salt from which methionine can be isolated.